ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives $7.14 Consensus Target Price from Analysts

ProQR Therapeutics N.V. (NASDAQ:PRQR) has been assigned a consensus rating of “Moderate Buy” from the nine ratings firms that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $7.1429.

PRQR has been the subject of several research reports. Chardan Capital reissued a “buy” rating and issued a $4.00 target price on shares of ProQR Therapeutics in a research note on Tuesday, November 4th. Weiss Ratings reiterated a “sell (d-)” rating on shares of ProQR Therapeutics in a research report on Thursday, January 22nd. Finally, Zacks Research raised ProQR Therapeutics from a “strong sell” rating to a “hold” rating in a report on Thursday, November 13th.

ProQR Therapeutics Price Performance

Shares of ProQR Therapeutics stock opened at $1.46 on Tuesday. The firm has a 50 day simple moving average of $1.85 and a 200 day simple moving average of $2.13. ProQR Therapeutics has a fifty-two week low of $1.07 and a fifty-two week high of $3.10. The firm has a market cap of $153.61 million, a P/E ratio of -3.11 and a beta of 0.20.

Institutional Trading of ProQR Therapeutics

A number of institutional investors have recently bought and sold shares of PRQR. Jane Street Group LLC lifted its stake in shares of ProQR Therapeutics by 699.3% in the 1st quarter. Jane Street Group LLC now owns 91,120 shares of the biopharmaceutical company’s stock valued at $121,000 after purchasing an additional 79,720 shares during the period. Vontobel Holding Ltd. increased its holdings in ProQR Therapeutics by 76.5% in the second quarter. Vontobel Holding Ltd. now owns 63,979 shares of the biopharmaceutical company’s stock valued at $131,000 after purchasing an additional 27,722 shares during the last quarter. Sio Capital Management LLC lifted its stake in ProQR Therapeutics by 1.0% in the second quarter. Sio Capital Management LLC now owns 2,075,139 shares of the biopharmaceutical company’s stock valued at $4,233,000 after buying an additional 20,546 shares during the period. Walleye Capital LLC boosted its holdings in ProQR Therapeutics by 5.6% during the second quarter. Walleye Capital LLC now owns 531,977 shares of the biopharmaceutical company’s stock worth $1,085,000 after buying an additional 28,413 shares during the last quarter. Finally, Affinity Asset Advisors LLC boosted its holdings in ProQR Therapeutics by 6.5% during the second quarter. Affinity Asset Advisors LLC now owns 3,499,512 shares of the biopharmaceutical company’s stock worth $7,139,000 after buying an additional 215,000 shares during the last quarter. Institutional investors and hedge funds own 32.65% of the company’s stock.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.